CA2476006A1 - Egf/egfr complex - Google Patents
Egf/egfr complex Download PDFInfo
- Publication number
- CA2476006A1 CA2476006A1 CA2476006A CA2476006A CA2476006A1 CA 2476006 A1 CA2476006 A1 CA 2476006A1 CA 2476006 A CA2476006 A CA 2476006A CA 2476006 A CA2476006 A CA 2476006A CA 2476006 A1 CA2476006 A1 CA 2476006A1
- Authority
- CA
- Canada
- Prior art keywords
- coordinate
- egfr
- egf
- atom
- ang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108060006698 EGF receptor Proteins 0.000 title description 136
- 238000000034 method Methods 0.000 claims abstract description 104
- 230000000694 effects Effects 0.000 claims abstract description 72
- 239000013078 crystal Substances 0.000 claims abstract description 71
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 238000012216 screening Methods 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 90
- 230000027455 binding Effects 0.000 claims description 57
- 239000000126 substance Substances 0.000 claims description 55
- 230000001105 regulatory effect Effects 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 125000000539 amino acid group Chemical group 0.000 claims description 42
- 238000006471 dimerization reaction Methods 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 230000002209 hydrophobic effect Effects 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 14
- 230000003993 interaction Effects 0.000 claims description 11
- 229940122558 EGFR antagonist Drugs 0.000 claims description 9
- 239000000539 dimer Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 101100074330 Caenorhabditis elegans lec-8 gene Proteins 0.000 claims description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 101150039808 Egfr gene Proteins 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 88
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 82
- 229910052739 hydrogen Inorganic materials 0.000 claims 36
- 239000001257 hydrogen Substances 0.000 claims 36
- 125000003118 aryl group Chemical group 0.000 claims 24
- 238000010256 biochemical assay Methods 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 abstract 2
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 230000000447 dimerizing effect Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 101150087199 leuA gene Proteins 0.000 description 321
- WQVJUBFKFCDYDQ-BBWFWOEESA-N leubethanol Natural products C1=C(C)C=C2[C@H]([C@H](CCC=C(C)C)C)CC[C@@H](C)C2=C1O WQVJUBFKFCDYDQ-BBWFWOEESA-N 0.000 description 265
- 101100501444 Escherichia phage P1 17 gene Proteins 0.000 description 260
- 101000588749 Homo sapiens N-acetylglutamate synthase, mitochondrial Proteins 0.000 description 200
- 102100032618 N-acetylglutamate synthase, mitochondrial Human genes 0.000 description 200
- 241000623377 Terminalia elliptica Species 0.000 description 194
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 185
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 180
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 180
- 102000001301 EGF receptor Human genes 0.000 description 135
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 description 130
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 130
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 88
- 101800003838 Epidermal growth factor Proteins 0.000 description 66
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 66
- 229940116977 epidermal growth factor Drugs 0.000 description 65
- 102400001368 Epidermal growth factor Human genes 0.000 description 50
- 108060008646 TRPA Proteins 0.000 description 45
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 44
- 101000743798 Homo sapiens Zinc finger HIT domain-containing protein 1 Proteins 0.000 description 38
- 102100039044 Zinc finger HIT domain-containing protein 1 Human genes 0.000 description 38
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 26
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 26
- 102100027819 Cytosolic beta-glucosidase Human genes 0.000 description 23
- 101000859692 Homo sapiens Cytosolic beta-glucosidase Proteins 0.000 description 23
- 101000997662 Homo sapiens Lysosomal acid glucosylceramidase Proteins 0.000 description 23
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 description 18
- 101000870042 Homo sapiens Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- MJEREOGWNZGKRN-UHFFFAOYSA-N 1-(4-aminophenyl)-8-[4-(4-fluorophenyl)-4-oxobutyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(N)=CC=C1N1C2(CCN(CCCC(=O)C=3C=CC(F)=CC=3)CC2)C(=O)NC1 MJEREOGWNZGKRN-UHFFFAOYSA-N 0.000 description 16
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 16
- 125000004429 atom Chemical group 0.000 description 16
- 230000001376 precipitating effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 101710085469 CD2 homolog Proteins 0.000 description 13
- 239000012460 protein solution Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 7
- 101000701051 Legionella pneumophila Zinc metalloproteinase Proteins 0.000 description 7
- 102000045108 human EGFR Human genes 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 101100149312 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SER1 gene Proteins 0.000 description 6
- 102000027549 TRPC Human genes 0.000 description 6
- 108060008648 TRPC Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 6
- 102000010553 ALAD Human genes 0.000 description 5
- 101150082527 ALAD gene Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000002447 crystallographic data Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 101150055960 hemB gene Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000005469 synchrotron radiation Effects 0.000 description 4
- 101150084418 EGF gene Proteins 0.000 description 3
- 229940084577 EGFR agonist Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000012835 hanging drop method Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- SAMYCKUDTNLASP-UHFFFAOYSA-N hexane-2,2-diol Chemical compound CCCCC(C)(O)O SAMYCKUDTNLASP-UHFFFAOYSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150052216 MET8 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 101100118551 Mus musculus Egfr gene Proteins 0.000 description 1
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100506037 Oryza sativa subsp. japonica GLU8 gene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001057593 Rattus norvegicus Pro-epidermal growth factor Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100064553 Solanum tuberosum GLUB3 gene Proteins 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000008071 UALB Methods 0.000 description 1
- 238000005162 X-ray Laue diffraction Methods 0.000 description 1
- FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000011102 hetero oligomerization reaction Methods 0.000 description 1
- 238000002017 high-resolution X-ray diffraction Methods 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108700016418 rat Egfr Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002028780 | 2002-02-05 | ||
| JP2002-28780 | 2002-02-05 | ||
| PCT/JP2002/009332 WO2003066677A1 (fr) | 2002-02-05 | 2002-09-12 | Complexe egf/egfr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2476006A1 true CA2476006A1 (en) | 2003-08-14 |
Family
ID=27677869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2476006A Abandoned CA2476006A1 (en) | 2002-02-05 | 2002-09-12 | Egf/egfr complex |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7514240B2 (ja) |
| EP (1) | EP1479693A4 (ja) |
| JP (1) | JPWO2003066677A1 (ja) |
| AU (1) | AU2002338064A1 (ja) |
| CA (1) | CA2476006A1 (ja) |
| WO (1) | WO2003066677A1 (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028499A2 (en) * | 2003-09-19 | 2005-03-31 | The Scripps Research Institute | Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom |
| MXPA06012294A (es) * | 2004-04-22 | 2007-03-15 | Johnson & Johnson | Complejos de proteina diminuta doble 2 humana-inhibidor y usos de los mismos. |
| JP2008509888A (ja) * | 2004-06-30 | 2008-04-03 | モレキュラー ロジックス，インコーポレイテッド | 上皮成長因子受容体アンタゴニストおよび使用方法 |
| JP2009089602A (ja) * | 2006-01-30 | 2009-04-30 | Meiji Seika Kaisha Ltd | エノイル−アシルキャリアプロテインレダクターゼ（ＦａｂＫ）の結晶 |
| EP2049568A2 (en) | 2006-04-07 | 2009-04-22 | Københavns Universitet | Erbb receptor-derived peptide fragments |
| WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
| US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| US8618302B2 (en) | 2010-01-06 | 2013-12-31 | Joseph P. Errico | Methods and compositions of targeted drug development |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| KR102452767B1 (ko) | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US10125193B2 (en) | 2014-02-14 | 2018-11-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| EP3215534B1 (en) * | 2014-11-05 | 2020-04-15 | Board of Regents, The University of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003522525A (ja) | 1999-11-19 | 2003-07-29 | ノバルティス アクチエンゲゼルシャフト | 細胞表面選択マーカー遺伝子 |
-
2002
- 2002-09-12 CA CA2476006A patent/CA2476006A1/en not_active Abandoned
- 2002-09-12 EP EP02772848A patent/EP1479693A4/en not_active Withdrawn
- 2002-09-12 WO PCT/JP2002/009332 patent/WO2003066677A1/ja active Application Filing
- 2002-09-12 JP JP2003566048A patent/JPWO2003066677A1/ja active Pending
- 2002-09-12 US US10/503,486 patent/US7514240B2/en not_active Expired - Fee Related
- 2002-09-12 AU AU2002338064A patent/AU2002338064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1479693A1 (en) | 2004-11-24 |
| WO2003066677A1 (fr) | 2003-08-14 |
| EP1479693A4 (en) | 2005-07-27 |
| AU2002338064A1 (en) | 2003-09-02 |
| US20070032637A1 (en) | 2007-02-08 |
| JPWO2003066677A1 (ja) | 2005-05-26 |
| US7514240B2 (en) | 2009-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2476006A1 (en) | Egf/egfr complex | |
| Rooney et al. | The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells | |
| AU759378B2 (en) | Three-dimensional structures and models of Fc receptors and uses thereof | |
| Warne et al. | Development and crystallization of a minimal thermostabilised G protein-coupled receptor | |
| Calvo et al. | Structure of the carboxy-terminal receptor-binding domain of avian reovirus fibre sigmaC | |
| US7129072B1 (en) | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor | |
| Zhu et al. | Structure of protein O-mannose kinase reveals a unique active site architecture | |
| US20050187150A1 (en) | Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds | |
| WO2020147297A1 (zh) | 一种抗egfr全人源化单克隆抗体的纯化工艺 | |
| Wu et al. | Regulation of mammalian transcription by Gdown1 through a novel steric crosstalk revealed by cryo‐EM | |
| US7754458B2 (en) | Crystal structure of the complex of hepatocyte growth factor beta chain with met receptor and methods of use | |
| He et al. | Single methyl groups can act as toggle switches to specify transmembrane Protein-protein interactions | |
| CA2490023A1 (en) | Crystal of glucokinase protein, and method for drug design using the crystal | |
| WO2020147298A1 (zh) | 一种用于制备抗egfr全人源化单克隆抗体的细胞株构建方法 | |
| Layton et al. | Identification of a ligand-binding site on the granulocyte colony-stimulating factor receptor by molecular modeling and mutagenesis | |
| US7294706B2 (en) | Identification of receptor and heparin binding sites in FGF4 by structure-based mutagenesis | |
| JP2005531485A (ja) | Ｒａｎｋリガンドの結晶形態および変異体 | |
| KR20190109398A (ko) | 태아알콜증후군 장애(fasd)의 치료를 위한 태반 성장인자 | |
| CA2382812A1 (en) | Crystal structures of domains of receptor protein tyrosine kinases and their ligands | |
| CN108864258A (zh) | 具有抑制肿瘤功能的peg化多肽及其制备方法与应用 | |
| US7498157B2 (en) | Three-dimensional structure of dipeptidyl peptidase IV | |
| DE60120410T2 (de) | Modulation der tetraspanin funktion | |
| US9896497B2 (en) | Toll-like receptor 2 binding epitope and binding member thereto | |
| Calvanese et al. | Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor | |
| KR101821345B1 (ko) | 유비퀴틴 특이적 프로테아제 활성을 갖는 단백질 usp47, 이의 3차원구조 및 이를 이용한 유비퀴틴 특이적 프로테아제의 저해제 개발 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |